Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

European Journal of Pharmacology

Volumn 779, Issue , 2016, Pages 8-21

  Herrero, Soledad ^a   Pico, Yolanda ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bisphosphonate; Cathepsin K; Denosumab; Long term Treatment; Postmenopausal Osteoporosis; Romosozumab

Indexed keywords

ALENDRONIC ACID; BALICATIB; BAZEDOXIFENE; BLOSOZUMAB; CALCITONIN; CATHEPSIN K INHIBITOR; DENOSUMAB; ESTROGEN DERIVATIVE; IBANDRONIC ACID; ODANACATIB; ONO 5334; PARATHYROID HORMONE[1-34]; RALOXIFENE; RELACATIB; RISEDRONIC ACID; ROMOSOZUMAB; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE MASS; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG TERM CARE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OSSIFICATION; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTOR;

FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 84963623282     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.02.053     Document Type: Review

References (51)

1. AEMPS, 2014. Drug Description, (drug safety). (risk communications Ref 2009/10, last accesed on 13.10.14).
2. American College of Rheumatology, 2014. Teriparatide (Forteo™) for the treatment of osteoporosis. (accessed 30.07.14).
3. Amgen Ilt, 2014. Romosozumab clinical trials. (accessed 01.01.14).
4. D.M. Black, S.R. Cummings, D.B. Karpf, and et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group Lancet 348 9041 1996 1535 1541
5. D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Cauley, S. Levis, S.A. Quandt, and et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial JAMA 296 2006 2927 2938
6. H.G. Bone, D. Hosking, J.P. devogelaer, J.R. Tucci, R.D. Emkey, R.P. Tonino, and et al. Ten years' experience with alendronate for osteoporosis in postmenoupausal women N. Engl. J. Med. 350 2004 1189 1199
7. C.H. Chesnut, S. Silverman, K. Andriano, and et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group Am J. Med. 109 4 2000 267 276
8. C.H. Chesnut, A. Skag, C. Christiansen, and et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J. Bone Miner. Res. 19 18 2004 1241 1249
9. Clinical Trials, 2014. (accessed October 30.10.14).
10. J.E. Compston, and J.P. Bilezikian Bisphosphonate therapy for osteoporosis: the long and short of it J. Bone Miner. Res. 27 2 2012 240 242 February
11. A. Cristiano, F. Zerbini, R. Michael, and McClung Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence Ther. Adv. Musculoskelet. Dis. 5 4 2013 199 209
12. S.R. Cummings, J. San Martin, M.R. McClung, Denosumab for prevention of fractures in postmenopausal women with osteoporosis N. Engl. J. Med. 361 8 2009 756 765 (Erratum in: N Engl J Med. 2009;361[19]:1914).
13. (b) S.R. Cummings, J. San Martin, M.R. McClung, N Engl J Med 361, 19 2009, 1914, (Erratum).
14. Dima L. Diab, B. Nelson, and Watts Bisphosphonate drug holiday: who, when and how long Ther. Adv. Musculoskelet. Dis. 5 2013 107 111 Jun
15. E.F. Eriksen, A. Díez-Pérez, and S. Boonen Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review Bone 58 2014 126 135
16. B. Ettinger, D.M. Black, B.H. Mitlak, and et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators JAMA 18 7 1999 637 645 (Erratum in: JAMA.1999;282[22]:2124)
17. B. Ettinger D.M. Black, and B.H. Mitlak JAMA 282 22 1999 2124 (Erratum)
18. European Medicines Agency, 2014. (accessed 09.07.14).
19. FDA webpage, 2014. (Available at): (accessed 09.07.14).
20. J.S. Finkelstein, J.J. Wyland, H. Lee, and R.M. Neer Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis J. Clin. Endocrinol. Metab. 95 4 2010 1838 1845 10.1210/jc.2009-1703 Epub 2010 Feb 17
21. S.J. Gallacher, and T. Dixon Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate and denosumab) on bone quality: a systematic review Calcif. Tissue Int. 87 2010 469 484
22. S. Gamsjaeger, B. Buchinger, R. Zoehrer, R. Phipps, K. Klaushofer, and E.P. Paschalis Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate Bone 49 6 2011 1160 1165 10.1016/j.bone.2011.08.015 Epub 2011 Aug 27
23. J. González Macías, N. Guañabens Gay, C. Gómez Alonso, L. Del Río Barquero, M. Muñoz Torres, M. Delgado, L. Pérez Edo, B. Díaz López, E. Jódar Gimeno, F. Hawkins Carranza (Comitéde Redacción, en representación del Comitéde Expertos de la SEIOMM para la elaboración de las Guías), 2008. Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM). < www.seiomm.org >.
24. B. Gullberg, O. Johnell, and J.A. Kanis Worldwide projections for HIP fracture Osteoporos. Int. 7 1997 407 413
25. International Osteoporosis Foundation. (accessed 30.07.14).
26. J. Jon Power, Kenneth E.S. Poole, Rutger van Bezooijen, Michael Doube, Ana M. Caballero-AlIas, Clemens Lowik, Socrates Papapoulos, Jonathan Reeve, and Nigel Loveridge clerostin and the Regulation of Bone Formation: Effects in Hip Osteoarthritis and Femoral Neck Fracture J. Bone Miner. Res. 25 8 2010 Article first published online: 23Feb2010
27. J.A. Kanis, O. Johnell, C. De Laet, H. Johansson, A. Oden, P.D. Delmas, J.A. Eisman, S. Fujiwara, P. Garnero, H. Kroger, E.V. McCloskey, D. Mellstrom, L.J. Melton, H. Pols, J. Reeve, A. Silman, and A. Tenenhouse A meta-analysis of previous fracture and subsequent fracture risk Bone 35 2 2004 375 382
28. A. Khan, M. Fortier, R. Reid, B.L. Abramson, J. Blake, S. Desindes, S. Dodin, L. Graves, B. Guthrie, S. Johnston, A. Khan, T. Rowe, N. Sodhi, P. Wilks, and W. Wolfman Osteoporosis in menopause J. Obstet. Gynaecol. Can. 36 9 2014 839 840
29. S. Kumar, L. Dare, J.A. Vasko-Moser, I.E. James, S.M. Blake, D.J. Rickard, S.M. Hwang, T. Tomaszek, D.S. Yamashita, R.W. Marquis, H. Oh, J.U. Jeong, D.F. Veber, M. Gowen, M.W. Lark, and G. Stroup A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in An acute model of elevated bone turnover in vivo in monkeys Bone 40 1 2007 122 131
30. E.R. Larsen, L. Mosekilde, and A. Foldspang Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study J. Bone Miner. Res. 19 3 2004 370 378
31. K.W. Lyles, C.S. Colón-Emeric, J.S. Magaziner, and et al. Zoledronic acid and clinical fractures and mortality after HIP fracture N. Eng. J. Med. 357 18 2007 1799 1809
32. J. Marjoribanks, C. Farquhar, H. Roberts, and A. Lethaby Long term Hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst. Rev. 7 2012 CD004143 10.1002/14651858.CD004143.pub4
33. D.D. Mellstom, O.H. Sorensen, S. Goemaere, c Roux, T.D. Jhonson, and A.A. Chines Seven years of treatment with risendronate in women with postmenopausal osteoporosis Calif. Tissue Int. 75 2004 462 468
34. L.J. Melton, E.J. Atkinson, C. Cooper, W.M. O'Fallon, and B.L. Riggs Vertebral fractures predict subsequent fractures Osteoporos. Int. 10 1999 214 221
35. P.D. Miller, R.R. Recker, J.Y. Reginster, B.J. Riis, E. Czerwinski, D. Masanauskaite, and et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long term extension study Osteoporos. Int. 23 2012 1747 1756
36. M. Muñoz-Torres, G. Alonso, and M.P. Raya Calcitonin therapy in osteoporosis Treat. Endocrinol. 3 2 2004 117 132
37. National Osteoporosis Foundation, 2014. Clinician's guide to prevention and treatment of osteoporosis. (accessed 09.07.14).
38. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, and et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 19 2001 1434 1441
39. S. Pervhal, J.H. Krege, P. Chen, H. Genant, and D.M. Black Teripatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment Curr. Med. Res. Opin. 25 4 2009 921 928 PubMed.gov
40. J. Reginster, D. Felsenberg, S. Boonen, A. Díez-Pérez, R. Rizzoli, M. Brandi, T. Spector, K. Brixen, S. Goemaere, C. Cormier, A. Balogh, P. Delmas, and P. Meunier Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-years, randomized, placebo-controlled trial Arthritis Rheum. 58 6 2008 1687 1695
41. J. Reginster, H.W. Minne, O.H. Sorensen, and et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group Osteoporos. Int. 11 1 2000 83 91
42. T.M. Rünger, S. Adami, C.L. Benhamou, E. Czerwiński, J. Farrerons, D.L. Kendler, L. Mindeholm, G. Realdi, C. Roux, and V. Smith Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib J. Am Acad. Dermatol. 66 3 2012 e89 e96
43. A.V. Schwartz, D.C. Bauer, S.R. Cummings, J.A. Cauley, K.E. Ensrud, L. Palermo, and et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial J. Bone Miner. Res. 25 2010 976 982
44. SEIOMM, 2015. Guias de práctica clínica en la osteoporosis post-menopáusica, glucocorticoidea y del varón. SEIOMM 2014. (accessed 18.07.15).
45. O.H. Sorensen, G.M. Crawford, H. Mulder, D.J. Hosking, C. Gennari, D. Mellstrom, S. Pack, D. Wenderoth, C. Cooper, and J.Y. Register Long-term efficacy of risendronate: a 5-years placebo-controlled clinical experience Bone 32 2 2003 120 126
46. O. Ström, F. Borgström, J.A. Kanis, J. Compston, C. Cooper, E. McCloskey, and B. Jönsson Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 2011 10.1007/s11657-011-0060-1
47. T. Sugiyama, T. Torio, T. Miyajima, Y. Kim Taek, and H. Oda Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis Front. Endocrinol. 21 2015 10.3389/fendo.2015.00054 Apr
48. R.P. Tonino, P.J. Meunier, R. Emkey, J.A. Rodriguez-Portales, C.J. Menkes, R.D. Wasnich, and et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group J. Clin. Endocrinol. Metab. 85 2000 3109 3115
49. M. Trapero-Bertrán, R. Puig-Peiró and L. Pellisé, 2012. Systematic Review of eConomic Evaluations done from Treatments used for Fracture Prevention in Post-menopausal Osteoporotic Women. Pompeu Fabra University. Updated from 2008 to 2012. 26 Nov, 2012.
50. World Health Organization, 1994. (accessed 30.07.14).
51. Yasuo Ochi, Hiroyuki Yamada, Hiroshi Mori, Yasutomo Nakanishi, Satoshi Nishikawa, Ryoji Kayasuga, Naoki Kawada, Akiko Kunishige, Yasuaki Hashimoto, Makoto Tanaka, Masfumi Sugitani, and Kazuhito Kawabata Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys Bone 65 2014 1 8 Minase Research Institute, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai Shimamoto-cho Mishima-gun, Osaka 618-8585, Japan. Received: August 7, 2013; Received in revised form: April 21, 2014; Accepted: April 21, 2014; Published Online: April 27, 2014